Poggesi L, Masotti G, Boddi M, Neri Serneri G G
Clin Pharmacol Ther. 1987 Mar;41(3):344-50. doi: 10.1038/clpt.1987.37.
The antihypertensive effects of indenolol, a new not-cardioselective beta-blocking agent, were evaluated in patients with WHO grades I and II essential hypertension (range 160/95 to 200/115 mm Hg) in a double-blind, placebo-controlled study after acute (12 patients) and 2-week treatment (seven patients). Indenolol (30 to 120 mg) reduced blood pressure in a dose-dependent fashion. Maximum reduction was 26 mm Hg for systolic and 17 mm Hg for diastolic pressure. Hypotensive activity commenced within 10 minutes, peaked in 60 minutes, and persisted for about 7 hours. Lower limb vascular resistance (strain-gauge plethysmography) was significantly lowered, thus suggesting an intrinsic sympathomimetic activity. Heart rate was progressively reduced at 30 and 60 mg without any additional effect at 120 mg. Indenolol did not alter adrenergic reflexes (standing, cold application, and hand-grip) and did not induce any side effect. In conclusion, indenolol possesses an antihypertensive activity associated with reduction of vascular resistance.
在一项双盲、安慰剂对照研究中,对12例急性治疗患者和7例经过2周治疗的世界卫生组织I级和II级原发性高血压(血压范围为160/95至200/115毫米汞柱)患者评估了新型非心脏选择性β受体阻滞剂茚萘洛尔的降压效果。茚萘洛尔(30至120毫克)以剂量依赖方式降低血压。收缩压最大降幅为26毫米汞柱,舒张压最大降幅为17毫米汞柱。降压活性在10分钟内开始,60分钟时达到峰值,并持续约7小时。下肢血管阻力(应变计体积描记法)显著降低,提示其具有内在拟交感活性。30毫克和60毫克剂量时心率逐渐降低,120毫克剂量时无额外效果。茚萘洛尔不改变肾上腺素能反射(站立、冷刺激和握力试验),也未引起任何副作用。总之,茚萘洛尔具有与血管阻力降低相关的降压活性。